Herbert Irving Comprehensive Cancer Center

VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM

Retrieved on: 
Thursday, September 7, 2023
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Herbert Irving Comprehensive Cancer Center, GBM, Cytomegalovirus, Clinical trial, Neuro-Oncology (journal), Physician, Survival, Hope, Toxicity, VBI, Associate, Glioblastoma, Combination therapy, HIV disease progression rates, Patient, Standard of care, Columbia University Vagelos College of Physicians and Surgeons, CMV, Decompression (diving), Mortality, Neoplasm, Neuro, MOS, NCI, Vaccine, Safety, Disease, Pharmaceutical industry, Surgeon

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the first patients have been dosed in the randomized, controlled Phase 2b study of VBI’s cancer vaccine immunotherapeutic candidate, VBI-1901, in patients with first recurrent glioblastoma (rGBM).

Key Points: 
  • VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the first patients have been dosed in the randomized, controlled Phase 2b study of VBI’s cancer vaccine immunotherapeutic candidate, VBI-1901, in patients with first recurrent glioblastoma (rGBM).
  • The study will assess the safety, tolerability, tumor response rates, and survival following treatment with VBI-1901, as a monotherapy, at 10 leading neuro-oncology centers across the United States.
  • As we work to offer new hope to the patients, family members, and caretakers who are battling this devastating and historically treatment-resistant brain tumor, we are excited to kick-off this next phase of development for VBI-1901.”
    In the Phase 1/2a study of VBI-1901 in the rGBM setting, extensive biomarker panels suggested normal baseline CD4+/CD8+ T-cell ratios, which is a measure of immunological fitness, along with boosting of cytomegalovirus (CMV) gB specific antibody responses were correlated with tumor and clinical responses.
  • These learnings have been incorporated into patient enrollment eligibility criteria for the Phase 2b study to help identify patient populations that may be more likely to respond to treatment with VBI-1901.

Boston Children's Hospital names Wendy Chung, MD, PhD, Chief of the Department of Pediatrics

Retrieved on: 
Tuesday, February 14, 2023
HMS, Medical director, Cornell University, Mentorship, Columbia University Irving Medical Center, Simons Foundation Autism Research Initiative, SPARK, Personalized medicine, Organization, Weill Cornell Medicine, Boston, NIH, Division, Columbia University, Education, Teaching, Hospital, Rockefeller University, Harvard Medical School, Morgan Stanley Children's Hospital, Research, SFARI, Genetics, Herbert Irving Comprehensive Cancer Center, Associate, Spectrum, Economics, Herbert, Doctor of Philosophy, Nursing, Pediatrics, Biochemistry, Boston Children's Hospital, Medicine, MD

BOSTON, Feb. 14, 2023 /PRNewswire/ -- Boston Children's Hospital has named Wendy Chung, MD, PhD, the hospital's next Chief of the Department of Pediatrics.

Key Points: 
  • BOSTON, Feb. 14, 2023 /PRNewswire/ -- Boston Children's Hospital has named Wendy Chung, MD, PhD, the hospital's next Chief of the Department of Pediatrics.
  • Dr. Chung will be responsible for leadership, strategy, oversight, and vision for the Department of Pediatrics, ensuring alignment with the goals, strategic priorities and mission of Boston Children's, the Physician's Organization, and Harvard Medical School.
  • In addition to her role as Chief of the Department of Pediatrics, Dr. Chung will serve as the Mary Ellen Avery Professor at Harvard Medical School (HMS), and President of the Children's Hospital Pediatric Associates.
  • "Dr. Chung is a tremendous addition to our Boston Children's team," says Kevin B. Churchwell, MD, President and CEO Boston Children's Hospital.

Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer

Retrieved on: 
Thursday, January 12, 2023
Regulatory T cell, Blood, Prostate cancer, Physician, Columbia University Irving Medical Center, Surgeon, Trial of the century, MDSC, Safety, TAAS, Columbia University Vagelos College of Physicians and Surgeons, MD, PSA, Herbert Irving Comprehensive Cancer Center, NK, Columbia University, Patient, Brachytherapy, Abstract, TME, OTCQX, Herbert, Columbia, Medicine, Prostate-specific antigen, LM, Pharmaceutical industry, Advaxis

MONMOUTH JUNCTION, N.J., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced an update on the Phase 1 clinical study evaluating ADXS-504, the company’s off-the-shelf neoantigen drug candidate, in patients with biochemically recurrent (early) prostate cancer that is being conducted at Columbia University Irving Medical Center. Karie Runcie, MD, assistant professor of medicine, and Mark N. Stein, MD, associate professor of medicine, in the division of hematology/oncology at Columbia University Vagelos College of Physicians and Surgeons and members of the Herbert Irving Comprehensive Cancer Center, are the study’s principal and senior investigators, respectively.

Key Points: 
  • The study design of this phase 1 open-label dose escalation study for patients in both dose cohorts was presented at the 2022 ASCO Annual Meeting by Dr. Runcie (Abstract #: TPS5115).
  • The trial is currently expanding enrollment at the second dose level by up to six additional patients for a total of nine patients.
  • “We have completed evaluation of the dose-limiting-toxicity period for three patients at the second dose level for this Phase 1 trial of ADXS-504.
  • We look forward to analyzing the composite data to gain further insight into the safety and efficacy of this novel therapy.”

Global Coalition for Adaptive Research Announces That Regorafenib Has Completed Follow-up in the GBM AGILE Trial for Patients With Glioblastoma

Retrieved on: 
Wednesday, September 21, 2022
Science, Neurology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Probability, National Foundation for Cancer Research, Regorafenib, Department, Dean (education), MD, Center, New, Health, Clinical trial, GBM, Herbert, Glioblastoma, United Nations Foundation, Patient, UCLA, Cancer, National Brain Tumor Society, Department of Neurology, Xuanwu hospital, Surgeon, MGMT, Radiation, Leadership, Coalition, Principal investigator, Columbia University Irving Medical Center, Associate, Arm, Herbert Irving Comprehensive Cancer Center, Lomustine, Global Coalition Against Pneumonia, Neurology, Sponsor, Temozolomide, Dana–Farber Cancer Institute, Columbia, Pharmaceutical industry, Medical device, Physician

Global Coalition for Adaptive Research (GCAR), Sponsor of GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment) master protocol, announced that regorafenib has completed enrollment and follow-up in GBM AGILE.

Key Points: 
  • Global Coalition for Adaptive Research (GCAR), Sponsor of GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment) master protocol, announced that regorafenib has completed enrollment and follow-up in GBM AGILE.
  • Regorafenib was being evaluated in GBM AGILE for efficacy in patients with recurrent glioblastoma and in patients with newly diagnosed MGMT unmethylated glioblastoma.
  • GBM AGILE is an international, innovative platform trial designed to identify effective therapies more rapidly for patients with glioblastoma through response adaptive randomization and a seamless phase 2/3 design.
  • GCAR is the sponsor of GBM AGILE, an adaptive platform trial for patients with GBM the most common and deadliest of malignant primary brain tumors.

Knowles Elects Science Education Scholar & Prominent Physician and Researcher as Trustees

Retrieved on: 
Monday, September 12, 2022
Friends' Central School, Hematology-Oncology and Stem Cell Transplantation Research Center, Faculty, Summer Enrichment Program (University of Colorado), Doctor of Philosophy, University, Cell biology, Director, New, Pediatrics, Augustus A. Bird, University of Michigan, Philosophy, Mathematics, Learning, Herbert, Harvard Graduate School of Education, Harvard University, Curriculum, University Medical Center, Happiness, Student, Leadership, Board of directors, Science, Friends, Board, Pathology, Associate, Herbert Irving Comprehensive Cancer Center, Harvard Educational Review, University of Washington Department of Bioengineering, Haverford College, Francis, Microbiology, Education, Chemistry, Tutoring, Trustee, Yale University, Medicine

"Both Dr. Braaten and Dr. Emerson are highly accomplished in the fields of science and education," said Lawrence Tint , Knowles Board of Trustees Chairman.

Key Points: 
  • "Both Dr. Braaten and Dr. Emerson are highly accomplished in the fields of science and education," said Lawrence Tint , Knowles Board of Trustees Chairman.
  • Previously, she worked as an assistant professor and director of the secondary science education program at the University of Wisconsin, Madison.
  • Notably, she co-authored a widely read and influential book, Ambitious Science Teaching (2018), through Harvard Education Press.
  • in education, both from the University of Tennessee, Knoxville, and a Ph.D. in curriculum and instruction and science education from the University of Washington.

MediciNova Announces Publication of MN-166 (ibudilast) Data regarding Prevention of Metastasis in Uveal Melanoma in Molecular Cancer Research

Retrieved on: 
Thursday, April 21, 2022
Code, Nasdaq, Herbert Irving Comprehensive Cancer Center, Tokyo Stock Exchange, NASDAQ, Mothers (Tokyo Stock Exchange), Columbia University Irving Medical Center, MD, Metastasis, MIF, Exosome, Associate, GLOBE, Hematology-Oncology and Stem Cell Transplantation Research Center, Doctor of Philosophy, Columbia University, Cell biology, Melanoma, UM, Hepatocyte, Macrophage migration inhibitory factor, Pathology, Columbia University Vagelos College of Physicians and Surgeons, Uveal melanoma, Physician, Cytokine, Molecular Cancer Research, Uvea, Research, Pharmaceutical industry, Vaccine, Medicine, Surgeon

The publication describes a preclinical study which characterized the proteomic content of uveal melanoma exosomes and identified the presence of markers with metastatic properties.

Key Points: 
  • The publication describes a preclinical study which characterized the proteomic content of uveal melanoma exosomes and identified the presence of markers with metastatic properties.
  • Key take-aways in the publication include:
    Uveal melanoma exosomes (UM-exo) induce activation of cell signaling pathways and the release of cytokines and growth factors from hepatocytes.
  • MIF blockade inhibited UM cell migration in co-cultures with exosome-stimulated hepatocytes and prevented the development of metastases in vivo.
  • This study provided the first in vivo evidence that MIF inhibition may serve as a novel adjuvant drug therapy to prevent metastasis in uveal melanoma.

Vivacitas Oncology Presents Its New Neuro-Oncology Advisor, Dr. Andrew Lassman MD, MS, FAAN

Retrieved on: 
Wednesday, December 15, 2021
Society, EVP, Coronavirus Scientific Advisory Board (Turkey), Pakistan Society of Neuro-Oncology, MS, College of Physicians & Surgeons of Mumbai, MSKCC, Toxicity, Herbert Irving Comprehensive Cancer Center, American Academy, Herbert, Biochemistry, Adult, Cancer, Clinical trial, Vivacitas, American Academy of Neurology, Columbia University, Columbia University Irving Medical Center, Immunotherapy, Pharmacokinetics, LP, Medical director, Research, Patient, Memorial Sloan Kettering Cancer Center, Molecular biology, Data, Associate, BS, Program, Glioma, MD, College, GLOBE, Neuro-Oncology (journal), Yale University, Precision medicine, New York (magazine), Surgeon, Medicine, Medical imaging, Pharmaceutical industry, Glioblastoma, Physician, Neurology, Amgen

WALNUT CREEK, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Vivacitas Oncology, Inc. ("Vivacitas" or the "Company"), a privately-held oncology company focused on tough-to-treat cancers, is pleased to announce the addition of Dr. Andrew Lassman to their Scientific Advisory Board.

Key Points: 
  • WALNUT CREEK, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Vivacitas Oncology, Inc. ("Vivacitas" or the "Company"), a privately-held oncology company focused on tough-to-treat cancers, is pleased to announce the addition of Dr. Andrew Lassman to their Scientific Advisory Board.
  • He completed his Neurology Residency at Columbia University (now Irving) Medical Center - New York Presbyterian Hospital.
  • He pursued a Neuro-Oncology Fellowship at MSKCC encompassing clinical training, clinical research, and bench science in the molecular biology of gliomas.
  • Through an enduring spirit, Vivacitas continues to apply clarity, tenacity and vision in our fight against aggressive cancers and our pursuit of new treatment options for patients and their families worldwide.

Caris Precision Oncology Alliance Announces the Addition of Columbia University Irving Medical Center to Its Collaborative Network of Precision Medicine Experts

Retrieved on: 
Thursday, November 18, 2021
Patient, American Securities, Protein, Environment, School, Industry, POA, Herbert Irving Comprehensive Cancer Center, Diagnosis, Cancer, MBA, Precision medicine, Herbert, Blood, National Cancer Institute, Database, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, Physician, DNA, Twitter, Research, Health, Incidence, Columbia University, Artificial intelligence, RNA, Hospital, NCI, Exome, FACP, Biomedical Research, Drug development, Disease, Intelligence, Quality of life, Medical imaging, Pharmaceutical industry

The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research.

Key Points: 
  • The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research.
  • The HICCC is the home for cancer research and patient care at Columbia University and NewYork-Presbyterian/Columbia University Irving Medical Center.
  • Their cancer center researchers and physicians are dedicated to understanding the complex biology behind cancer, from before it begins to its evolution and spread.
  • The Herbert Irving Comprehensive Cancer Center (HICCC) is the home for cancer research and patient care at Columbia University and NewYork-Presbyterian/Columbia University Irving Medical Center.

Rarecells, Inc. to fund a clinical study at Columbia University of its ISET® -AML test for early detection of Acute Myeloid Leukemia (AML)

Retrieved on: 
Tuesday, November 9, 2021
AML, University, Bone marrow, Cancer, Prostate, ISET, Columbia University Vagelos College of Physicians and Surgeons, Technology, Acute myeloid leukemia, Blood, Trial of the century, MDS, EC, Red blood cell, AI, Liquid biopsy, Myelodysplastic syndrome, Columbia University, Surgeon, Columbia, Physician, Herbert Irving Comprehensive Cancer Center, Patient, Prostate cancer, Risk, Pharmaceutical industry, Medical imaging

This clinical study aims to assess the clinical performance of the ISET -AML test in the context of early AML detection.

Key Points: 
  • This clinical study aims to assess the clinical performance of the ISET -AML test in the context of early AML detection.
  • Myelodysplastic syndromes are a group of diverse bone marrow disorders in which the bone marrow does not produce enough healthy blood cells.
  • We look forward to a continued progress across our ISET Early Cancer Detection program, which also includes ongoing studies in patients at risk of Prostate Cancer".
  • Rarecells, Inc.is a healthcare company focused on the development and commercialization of non-invasive Early Cancer Detection tests.